Adocia (XPAR:ADOC) Short Interest


XPAR:ADOC Adocia XPAR:ADOC
30 GF Score
Price €3.94
GF Value €0.91
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Adocia Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XPAR:ADOC vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Adocia's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adocia Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adocia's Short Interest distribution charts can be found below:

* The bar in red indicates where Adocia's Short Interest falls into.


XPAR:ADOC
30GF Score
Adocia XPAR:ADOC
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Adocia (XPAR:ADOC) Overvalued in 2026?

Based on GuruFocus' analysis, Adocia stock appears to be overvalued. The current stock price of €3.94 is trading 332.7% above its estimated GF Value™ of €0.91. GuruFocus considers Adocia to be Significantly Overvalued.

Key valuation signals for XPAR:ADOC:

  • Short Interest:
  • GF Value™: €0.91 vs. price of €3.94 (332.7% above fair value)
  • GF Score™: 30/100 with 7 warning signs

No single metric tells the full story. See the XPAR:ADOC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adocia Business Description

Other Exchanges 0QAI:UKA89:Germany
Address 115 Avenue Lacassagne, Lyon, FRA, 69003
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
30GF Score

Get the complete analysis for XPAR:ADOC

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.94
Price
€0.91
GF Value